The use of opioids in the treatment of osteoarthritis: When, why, and how?

Current Pain and Headache Reports

Volumn 9, Issue 6, 2005, Pages 390-398

  Goodwin, Jeremy L R ^a   Kraemer, Jan J ^a   Bajwa, Zahid H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; GASTROINTESTINAL AGENT; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANALGESIC ACTIVITY; ARTHRALGIA; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXERCISE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; HYPOGONADISM; INCIDENCE; INFORMED CONSENT; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER TOXICITY; LOW DRUG DOSE; NAUSEA; OPIATE ADDICTION; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SOMNOLENCE; TREATMENT FAILURE;

EID: 28944454515     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-005-0018-3     Document Type: Review

References (36)

1. Ahmedzai S: Recent clinical trials of pain control: impact on quality of life. Eur J Can 1995, 31A(suppl 6):S2-S7.
2. Pritzker K: Pathology of osteoarthritis. In Osteoarthritis, edn 2. Edited by Brandt K, Doherty M, Lohmander LS. Oxford: University Press; 2003:49-58.
3. Sutherland SP, Cook SP, McCleskey EW: Chemical mediators of pain due to tissues damage and ischemia. Prog Brain Res 2000, 129:21-28.
4. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
5. Centers for Disease Control: Impact of arthritis and other rheumatic conditions on the health-care system- United States. 1997. MMWR 1999, 48:349-353.
6. Nichol MB, Harada AS: Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis: a review. Pharmacoeconomics 1999, 16:433-448.
7. Giraudet-Le Quintrec JS, Coste J, Vastel L, et al.: Positive effect of patient education for hip surgery: a randomized trial. Clin Orthop Relat Res 2003, 414:112-120.
8. Tak E, Staats P, Van Hespen A, Hopman-Rock M: The effects of an exercise program for older adults with osteoarthritis of the hip. J Rheumatol 2005, 32:1106-1113.
9. McQuay HJ, Moore RA: An Evidenced-based Resource for Pain Relief. New York: Oxford University Press; 1998.
10. Schnitzer TJ: Update of ACR Guidelines for Osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002, 23:524-530.
11. Henrich WL, Agodoa LE, Barrett B, et al.: Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996, 27:162-165.
12. Rygnestad T, Zahlsen K, Samdal FA: Absorption of effervescent paracetamal tablets relative to ordinary paracetamal tablets in healthy volunteers. Eur J Clin Pharmacol 2000, 56:141-143.
13. Flowe RJ, Vane JR: Inhibition of prostaglandin synthetase in brain explains the anti-activity of paracetamol (4-acetamidophenol). Nature 1972, 240:410-411.
14. Chandrasekharan NV, Dai H, Ross KL, et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002, 99:13926-13931.
15. Bjordal JM, Ljunggren AE, Klovning A, et al.: Non-steroidal anti-inflammatory drugs, including coxibs, in osteoarthritic knee pain: a meta-analysis of randomized, placebo-controlled trials. BMJ 2004, 329:1317-1320.
16. Zhang W, Jones A, Doherty M: Does paracetamol reduce the pain of osteoarthritis? A meta-analysis of randomized, controlled trials. Ann Rheum Dis 2004, 63:901-907.
17. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915.
18. Grond S: Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43:879-923.
19. Raffa RB, Friderichs E, Reiman E, et al.: Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1992, 260:275-285.
20. Cicero TJ, Adams EH, Geller A: Assessment of tramadol abuse from April 5, 1995 until March 31, 2000: progress report of the Independent Steering Committee, USA 2000. ISC.
21. Lewis KS, Han NH: Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997, 54:643-652.
22. Fricke JR Jr, Karim R, Jordan D, et al.: A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. Clin Ther 2002, 24:953-968.
23. Cicero TJ, Inciardi JA, Adams EH, et al.: Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse-monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005, Epub ahead of print.
24. Gasse C, Derby L, Vasilakis-Scaramozza C, et al.: Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000, 20:629-634.
25. Emkey R, Rosenthal N, Wu SC, et al.: CAPSS-114 Study Group. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal anti-inflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004, 31:5-7.
26. Watson S, Arkinstall S: The G-protein Linked Receptor Facts Book. London: Academic Press; 1994.
27. Carvey PM: Drug Action in the Central Nervous System. New York: Oxford University Press;1998.
28. Bannwarth B: Risk-benefit assessment of opioids in chronic non-cancer pain. Drug Saf 1999, 21:283-296.
29. Pappagallo M, Heinberg LJ: Ethical issues in the management of chronic non-malignant pain. Semin Neurol 1997, 17:203-211.
30. Passik SD, Weinreb HJ: Managing chronic non-malignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000, 17:70-83.
31. Fishbain DA, Rosomoff HL, Rosomoff RS: Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992, 8:77-85.
32. Becker N, Bondergaard TA, Olsen AK, et al.: Pain epidemiology and health-related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997, 73:393-400.
33. Portenoy RK: Opioid therapy for chronic non-cancer pain. Can we get past the bias? Am Pain Soc Bull 1991, 1:4-7.
34. Hanks G, Cherny N: Opioid analgesic therapy. In Oxford Textbook of Palliative Medicine, edn 2. Edited by Doyle D, Hanks G, Macdonald N. Oxford: Oxford University Press; 1998:331-335.
35. Schimier J, Palmer C, Flood E, Gourlay G: Utility assessments of opioids treatment for chronic pain. Pain Med 2002, 3:218-230.
36. Hochberg M, Lixing L, Bausell B, et al.: Traditional Chinese acupuncture is effective as adjunctive therapy in patients with osteoarthritis of the knee. Arthritis Rheum 2004, 50:S644.